Hemodynamic effects of 5-aminolevulinic acid in humans.

[1]  P. Meissner,et al.  The acute porphyrias , 1997, The Lancet.

[2]  D. Kessel,et al.  Side effects and photosensitization of human tissues after aminolevulinic acid. , 1997, The Journal of surgical research.

[3]  Q. Peng,et al.  5‐Aminolevulinic Acid‐Based Photodynamic Therapy: Principles and Experimental Research , 1997, Photochemistry and photobiology.

[4]  J Moan,et al.  DISTRIBUTION OF 5‐AMINOLEVULINIC ACID‐INDUCED PORPHYRINS IN NODULOULCERATIVE BASAL CELL CARCINOMA , 1995, Photochemistry and photobiology.

[5]  N. F. Jensen,et al.  Anesthetic Considerations in Porphyrias , 1995, Anesthesia and analgesia.

[6]  A Gorchein,et al.  Photosensitisation and photodynamic therapy of oesophageal, duodenal, and colorectal tumours using 5 aminolaevulinic acid induced protoporphyrin IX--a pilot study. , 1995, Gut.

[7]  P. Speight,et al.  Photodynamic therapy of oral cancer: photosensitisation with systemic aminolaevulinic acid , 1993, The Lancet.

[8]  J Moan,et al.  Distribution and photosensitizing efficiency of porphyrins induced by application of exogenous 5‐aminolevulinic acid in mice bearing mammary carcinoma , 1992, International journal of cancer.

[9]  J C Kennedy,et al.  Endogenous protoporphyrin IX, a clinically useful photosensitizer for photodynamic therapy. , 1992, Journal of photochemistry and photobiology. B, Biology.

[10]  A Gorchein,et al.  Sustained high plasma 5‐aminolaevulinic acid concentration in a volunteer: no porphyric symptoms , 1992, European journal of clinical investigation.

[11]  S H Snyder,et al.  The peripheral‐type benzodiazepine receptor: a protein of mitochondrial outer membranes utilizing porphyrins as endogenous ligands , 1987, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[12]  S H Snyder,et al.  Porphyrins are endogenous ligands for the mitochondrial (peripheral-type) benzodiazepine receptor. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[13]  A. Basbaum,et al.  Labelling of peripheral-type benzodiazepine binding sites in human brain with [3H]PK 11195: Anatomical and subcellular distribution , 1987, Brain Research Bulletin.

[14]  G. Le Fur,et al.  Electrophysiological and pharmacological characterization of peripheral benzodiazepine receptors in a guinea pig heart preparation. , 1984, Life sciences.

[15]  M. Desban,et al.  Autoradiographic localization of peripheral benzodiazepine binding sites in the cat brain with [3H]PK 11195 , 1984, Brain Research Bulletin.

[16]  D. Douer,et al.  Treatment of acute intermittent porphyria with large doses of propranolol. , 1978, JAMA.

[17]  M. Beal,et al.  Catecholamine uptake, accumulation, and release in acute porphyria. , 1977, The Journal of clinical investigation.

[18]  N. Schoenfeld,et al.  The effect of beta-adrenergic blocking agents on experimental porphyria induced by 3,5-diethoxycarbonyl-1,4-dihydrocollindine (DDC) in vivo and in vitro , 1976 .

[19]  C. Magnussen,et al.  Acute intermittent porphyria: clinical and selected research aspects. , 1975, Annals of internal medicine.

[20]  H. Bonkowsky,et al.  Letter: Hazard of propranolol in treatment of acute prophyria. , 1974, British medical journal.

[21]  R. Ward,et al.  Acute Intermittent Porphyria: Response of Tachycardia and Hypertension to Propranolol , 1973, British medical journal.

[22]  D. Tschudy,et al.  ACUTE INTERMITTENT PORPHYRIA: A Clinical and Biochemical Study of 46 Patients , 1970, Medicine.

[23]  A. Neuberger,et al.  The metabolism of δ-aminolaevulic acid. 1. Normal pathways, studied with the aid of 15N , 1956 .

[24]  E G Hahn,et al.  Photodynamic therapy: successful destruction of gastrointestinal cancer after oral administration of aminolevulinic acid. , 1995, Gastrointestinal Endoscopy.

[25]  S. Snyder,et al.  Peripheral type benzodiazepine receptors. , 1989, Annual review of pharmacology and toxicology.